Blonanserin-induced Mood Alteration in Schizophrenia and Schizoaffective Disorder: Two Cases.
We report two outpatients, one with schizophrenia and one with schizoaffective disorder, who developed manic or hypomanic episodes following the initiation of blonanserin during the course of treatment. Blonanserin is a novel antipsychotic that acts as a 5-HT and D2 receptor antagonist. Both patients developed hypomanic episodes within 2 weeks of receiving a small dose (6-8 mg) of blonanserin, and one patient later developed full-blown mania; both episodes ended within 1 month of discontinuing blonanserin. The mood alteration observed in these cases suggests a possible antidepressant effect of blonanserin; thus, clinicians should monitor mood changes when administering this antipsychotic.
Department of Psychiatry, Hanyang University Medical Center, Hanyang University School of Medicine, Seoul, Korea.
Aran
A
Min
Department of Psychiatry, Hanyang University Medical Center, Hanyang University School of Medicine, Seoul, Korea.
Daeho
D
Kim
Antipsychotic agents; Bipolar disorder; Blonanserin; Psychotic disorders; Schizophrenia